Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Impact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses.

Putta MR, Yu D, Bhagat L, Wang D, Zhu FG, Kandimalla ER.

J Med Chem. 2010 May 13;53(9):3730-8. doi: 10.1021/jm100177p.

PMID:
20361743
2.

Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.

Putta MR, Zhu F, Li Y, Bhagat L, Cong Y, Kandimalla ER, Agrawal S.

Nucleic Acids Res. 2006 Jun 23;34(11):3231-8. Print 2006.

3.

Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.

Yu D, Putta MR, Bhagat L, Li Y, Zhu F, Wang D, Tang JX, Kandimalla ER, Agrawal S.

J Med Chem. 2007 Dec 13;50(25):6411-8. Epub 2007 Nov 8.

PMID:
17988082
4.

Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity.

Putta MR, Zhu FG, Wang D, Bhagat L, Dai M, Kandimalla ER, Agrawal S.

Bioconjug Chem. 2010 Jan;21(1):39-45. doi: 10.1021/bc900425s.

PMID:
20020767
5.

Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.

Vollmer J, Weeratna RD, Jurk M, Davis HL, Schetter C, Wüllner M, Wader T, Liu M, Kritzler A, Krieg AM.

J Leukoc Biol. 2004 Sep;76(3):585-93. Epub 2004 Jun 24.

PMID:
15218053
6.

Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9.

Yu D, Wang D, Zhu FG, Bhagat L, Dai M, Kandimalla ER, Agrawal S.

J Med Chem. 2009 Aug 27;52(16):5108-14. doi: 10.1021/jm900730r.

PMID:
19650625
7.

Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.

Yu D, Putta MR, Bhagat L, Dai M, Wang D, Trombino AF, Sullivan T, Kandimalla ER, Agrawal S.

Antimicrob Agents Chemother. 2008 Dec;52(12):4320-5. doi: 10.1128/AAC.00701-08. Epub 2008 Oct 13.

8.

Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists.

Jurk M, Kritzler A, Debelak H, Vollmer J, Krieg AM, Uhlmann E.

ChemMedChem. 2006 Sep;1(9):1007-14.

PMID:
16952134
9.

Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.

Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, Cong YP, Song SS, Tang JX, Sullivan T, Agrawal S.

Proc Natl Acad Sci U S A. 2005 May 10;102(19):6925-30. Epub 2005 Apr 28.

10.

Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.

Merlo A, Calcaterra C, Mènard S, Balsari A.

J Leukoc Biol. 2007 Sep;82(3):509-18. Epub 2007 Jun 22.

PMID:
17586660
11.

Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9.

Wang D, Bhagat L, Yu D, Zhu FG, Tang JX, Kandimalla ER, Agrawal S.

J Med Chem. 2009 Jan 22;52(2):551-8. doi: 10.1021/jm8014316.

PMID:
19102653
12.

Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.

Vollmer J.

Expert Opin Biol Ther. 2005 May;5(5):673-82. Review.

PMID:
15934842
13.

Necessity of oligonucleotide aggregation for toll-like receptor 9 activation.

Wu CC, Lee J, Raz E, Corr M, Carson DA.

J Biol Chem. 2004 Aug 6;279(32):33071-8. Epub 2004 Jun 7.

14.

Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.

Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, Selander KS.

Mol Cancer Res. 2008 Oct;6(10):1534-43. doi: 10.1158/1541-7786.MCR-07-2005.

15.

TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.

Daubenberger CA.

Curr Opin Mol Ther. 2007 Feb;9(1):45-52. Review.

PMID:
17330401
16.

DNA motifs suppressing TLR9 responses.

Trieu A, Roberts TL, Dunn JA, Sweet MJ, Stacey KJ.

Crit Rev Immunol. 2006;26(6):527-44. Review.

PMID:
17341193
17.

Effect of synthetic agonists of toll-like receptor 9 on canine lymphocyte proliferation and cytokine production in vitro.

Im Hof M, Williamson L, Summerfield A, Balmer V, Dutoit V, Kandimalla ER, Yu D, Zurbriggen A, Doherr MG, Peel J, Roosje PJ.

Vet Immunol Immunopathol. 2008 Jul 15;124(1-2):120-31. doi: 10.1016/j.vetimm.2008.03.002. Epub 2008 Mar 20.

PMID:
18452997
18.

Synthesis and immunological activities of novel agonists of toll-like receptor 9.

Struthers M, Bett AJ, Wisniewski T, Dubey SA, Precopio M, Jiang W, Sun Z, Wang H, Nowak I, Putta MR, Yu D, Tang JX, Kandimalla ER, Agrawal S, Casimiro DR.

Cell Immunol. 2010;263(1):105-13. doi: 10.1016/j.cellimm.2010.03.005. Epub 2010 Mar 10.

PMID:
20381019
19.

Synthesis, purification, and characterization of immune-modulatory oligodeoxynucleotides that act as agonists of Toll-like receptor 9.

Putta MR, Yu D, Kandimalla ER.

Methods Mol Biol. 2011;764:263-77. doi: 10.1007/978-1-61779-188-8_18.

PMID:
21748647
20.

Synthetic agonists of Toll-like receptors 7, 8 and 9.

Agrawal S, Kandimalla ER.

Biochem Soc Trans. 2007 Dec;35(Pt 6):1461-7. Review.

PMID:
18031246

Supplemental Content

Support Center